Quadriplegia Treatment Market: Advanced R&D Process StrategiesPosted by Ganesh Shinde on December 21st, 2022 In 2022, the Quadriplegia Treatment Market size is anticipated to be worth US,468.4 million. The global demand for quadriplegia therapy is anticipated to reach around US$ 2,324.4 Million by 2032, growing at a CAGR of 4.7% between 2022 and 2032. The demand for quadriplegia treatment will progressively rise, which will provide manufacturers with numerous favorable development opportunities in the near future. Key Drivers of Quadriplegia Treatment Market Quadriplegia is caused by spinal cord injury which is caused due to trauma at the base of the neck or skull. Some of the common causes of quadriplegia, otherwise known as tetraplegia are paralysis after any accident, tumors of the spinal cord or other spinal cord diseases. The injury to the spinal cord may cause partial or total limb paralysis. According to 2020 data sheet of Spinal Cord Injury Statistics, it was estimated that approximately 17,810 new cases of spinal cord injuries occur every year in the U.S. Some of the reasons for quadriplegia include stroke, vehicular accidents, falls, violence, sports, medical or surgical causes and others. According to WHO statistics, published in June 2021, 20-50 million people suffer from road traffic accidents every year which lead to non-fatal injuries yet permanent disabilities to them. With the increasing rate of road traffic accidents, the demand for quadriplegia treatment is set to show a positive growth over the forecast period. Recent technological advancements and various R&D activities in the field of quadriplegia treatment are one of the leading causes which will boost the demand for this market in forthcoming years. There is an increased level of awareness amongst the patients suffering from spinal cord injuries about various treatment options available to improve their quality of life. This is another factor which will propel the demand for various treatments for quadriplegia during the forecast market. Key player of Quadriplegia Treatment Market Major manufacturers of medications needed to treat quadriplegia are
In November 2020, Pfizer and Mylan announced the merger of Pfizer’s Upjohn generics unit and Mylan. This deal was a part of restructuring drive at Pfizer, which was aimed for stronger foothold in the innovative medicines division of the company. Key Segments By Treatment Type:
By Route of Administration:
By Distribution Channel:
Browse More Details@ https://www.futuremarketinsights.com/reports/quadriplegia-treatment-market Like it? Share it!More by this author |